Board of Directors
Mitchel Sayare, Ph.D.Chairman of the Board
Dr. Sayare was appointed to the Company’s Board of Directors in April 2010 and served as Chairman of the Board since January 2018. Most recently, he served as Chairman and Chief Executive Officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development of antibody-based cancer therapeutics. During his tenure with ImmunoGen, Dr. Sayare was responsible for leading a successful IPO and raising over $300 million in venture capital and public equity financing for the company. Dr. Sayare also served as President of the 95%-owned ImmunoGen subsidiary, Apoptosis Technology, where he was responsible for managing operations for the organization. Prior to joining ImmunoGen, Dr. Sayare served as Vice President, Development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer. In this role he oversaw all research and development, corporate development and investor relations responsibilities for the company. Dr. Sayare earned his Ph.D. in biochemistry from the Temple University School of Medicine and his undergraduate degree from Ursinus College.Chairman of the Board
David J. Drutz, MDDirector
Dr. Drutz was first elected to our board of directors in January 2010 and served as Chairman of the Board between October 2011 and December 2017. He is the President of Pacific Biopharma Associates, a biopharmaceutical consulting company that he founded in January 1999. Between 2008 and 2015, he served as Director (March 2008-December 2015), Chief Executive Officer (December 2011-June 2014), Executive Chairman (June 2014-December 2015) and Chief Medical Officer (January 2012-December 2015) of DARA BioSciences, an oncology supportive care company located in Raleigh, NC, which was acquired by Midatech Pharma in December 2015. Dr. Drutz served previously as Chairman of Tranzyme, Inc. (NASDAQ:TZYM, 2000-2010) acquired by Ocera Therapeutics (NASDAQ:OCRX); Director of MethylGene, Inc. (TSX:MYG, 2000-2010) acquired by Mirati Therapeutics (NASDAQ:MRTX); and Director of Gentris Corporation (2007-2014), acquired by Cancer Genetics (NASDAQ:CGIX). From 1999 to 2008 he was a general partner with Pacific Rim Ventures, a Tokyo-based international venture capital firm. He is a former member of the Science and Industry Advisory Committee (SIAC) of Genome Canada, which advises Genome Canada’s board of directors regarding genomics investments throughout Canada. Dr. Drutz’s management experience includes tenures as VP Biological Sciences and VP Clinical Research at Smith Kline & French Laboratories, VP Clinical Development at Daiichi Pharmaceutical Corporation, and CEO of Inspire Pharmaceuticals (1995-1998) and Sennes Drug Innovations (1994-1995). Earlier in his career, Dr. Drutz was Professor of Medicine and Chief of the Division of Infectious Diseases at the University of Texas Health Science Center, San Antonio, and prior to that appointment was Assistant Professor of Medicine and Chief of the Division of Infectious Diseases at the University of California, San Francisco/San Francisco General Hospital. Dr. Drutz received his M.D. from the University of Louisville School of Medicine and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer (infectious diseases) in the U.S. Navy with the rank of Lieutenant Commander. He is certified by the American Board of Internal Medicine, a fellow of the American College of Physicians and the Infectious Diseases Society of America, a member of the American Society of Clinical Oncology and the American Society for Clinical Investigation, and the author of more than 200 peer-reviewed articles, book chapters and abstracts for presentation. We believe Dr. Drutz’s experience in biotechnology investment and service as a board member and qualifications as a physician qualify him to serve as a member of our board of directors.
Mr. Hodges was first elected to our board of directors in September 2003 and is currently serving as chair of our audit committee. He is Managing Partner of Redmont Capital, a private equity firm located in Birmingham, Alabama, which he joined at its inception in 1997. Redmont Capital is a co-founder of our company. Mr. Hodges’ investment strategy is focused on high growth small businesses within the health care, life science and technology sectors. He currently serves as a director for several of the firm’s portfolio companies. Mr. Hodges holds a Bachelor of Science in Business Administration from the Brock School of Business at Samford University. We believe Mr. Hodges’ experience as a board member, life science investor and co founder qualifies him to serve as a member of our board of directors.
Brigadier General (ret.) Klaus O. Schafer, MD, MS, MPHDirector
Dr. Schafer has over 35 years of leadership experience, having held senior positions in government and industry. He has been a member of the board of directors since July 2012. He held the position of Deputy Assistant to the Secretary of Defense for chemical and biological defense, overseeing the Department of Defense $1.0 billion program for vaccine, therapeutics, medical device and sensor development. He retired from the Air Force as the Assistant Surgeon General and he accrued extensive experience managing all aspects of large integrated health care delivery systems and managing government science and technology portfolios. His private sector startup experience in telemedicine and as former CEO and co-founder of TessArae LLC, a biotech medical device company. He recently held the position of Chief Medical Officer and client executive for health at CACI International. He has been an independent consultant since 2002 and has served as advisory board member to a number of biotech and health related companies. Dr. Schafer earned his MD at the University of Iowa, medical boards in family practice and aerospace medicine, his MPH at the University of Texas, his MS at the Dwight D. Eisenhower School of National Security and Resource Strategy.
Wayne Pisano was elected to join the company’s Board in August of 2018. Mr. Pisano joined the board of directors of Provention Bio, Inc., a biopharmaceutical company, in April of 2018, and has served on the board of directors of Immunovaccine Inc., a biopharmaceutical company, since October 2011, and Oncolytics, Inc., a biotechnology company, since May 2013. Mr. Pisano served as president and CEO of VaxInnate, a biotechnology company, from January 2012 until November 2016. Mr. Pisano joined Sanofi Pasteur in 1997 and was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. He has a bachelor’s degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio. The Board believes that Mr. Pisano’s depth of experience across the spectrum of commercial operations, public immunization policies and pipeline development will make him a valuable member of our Board of Directors.
John M. GillDirector
Mr. Gill has served as President and Chief Executive Officer of PharmAthene since March 2015, and has been a member of the Company’s Board of Directors since 2004. Mr. Gill was a co-founder of TetraLogic Pharmaceuticals Corporation and served as its President and Chief Executive Officer from 2003 to 2013. Prior to co-founding TetraLogic Mr. Gill was Executive Vice President, Chief Operating Officer and a Director of 3-Dimensional Pharmaceuticals, a drug discovery and development company that was acquired by Johnson and Johnson during March 2003. Mr. Gill has previously held positions at SmithKline Beecham Corporation, now GlaxoSmithKline, where he served as a member of the Research and Development Executive Committee, Chairman of the Research and Development Operating Committee, Vice President Research and Development Operations and Finance, a founding member and partner of SR One Ltd., Chief Operating Officer of SK&F Nova Pharmaceuticals and earlier in a variety of finance roles. Mr. Gill is a Certified Public Accountant and served in the United States Marine Corps.
Vipin K. Garg, Ph.D.President and Chief Executive Officer
Dr. Garg currently serves as our President and CEO and is a member of the board of directors. He joined Altimmune in November 2018 with over three decades of experience in the biotechnology and pharmaceutical industries. He has a proven track record of building and managing both private and publicly traded companies. Before joining Altimmune, he served as President and CEO of Neos Therapeutics (Nasdaq: NEOS), where he built a commercial-stage biopharmaceutical company launching three branded therapeutic products including Adzenys XR- ODTTM and Cotempla XR-ODTTM the first ever XR-ODTTM medications for the treatment of ADHD. Prior to Neos, he served as president and CEO of Tranzyme Pharma where he progressed a discovery-stage, emerging biotech company to a Nasdaq-listed clinical-stage, drug development company. Prior to joining Tranzyme, Dr. Garg served as Chief Operating Officer of Apex Bioscence, Inc. (acquired by Curacyte AGof Munich, Germany), and held senior management positions at DNX Bio-Therapeutics, Inc. until its acquisition by Baxter Healthcare Corporation, Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc., now a subsidiary of Sumitomo Dainippon Pharma), and Bio-Response Inc.(acquired by Baxter Healthcare Corporation). Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of Adelaide, Australia, and his M.S. from IARI Nuclear Research Laboratory, New Delhi, India in 1978.